Treatment of intra-abdominal and skin and soft tissue infections: The role of the glycylcyclines

International Journal of Surgery

Volumn 4, Issue 1, 2006, Pages 45-52

  Homer Vanniasinkam, Shervanthi ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Complicated skin and soft tissue infections; Glycylcyclines; Intra abdominal infections; Tigecycline

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; CLOXACILLIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DICLOXACILLIN; FLUCLOXACILLIN; GLYCOPEPTIDE; GLYCYLCYCLINE DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; LINCOSAMIDE DERIVATIVE; LINEZOLID; MACROLIDE; METRONIDAZOLE; NAFCILLIN; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; PROTON PUMP INHIBITOR; SULTAMICILLIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTHRALGIA; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DIABETIC FOOT; DIARRHEA; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; DRUG SENSITIVITY; DYSPEPSIA; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFECTION COMPLICATION; INJECTION SITE IRRITATION; LICENSING; MULTIDRUG RESISTANCE; MYALGIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; OTOTOXICITY; PNEUMONIA; PRIORITY JOURNAL; RASH; REVIEW; SEIZURE; SKIN INFECTION; SOFT TISSUE INFECTION; VOMITING;

EID: 33645107270     PISSN: 17439191     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijsu.2005.11.004     Document Type: Review

References (50)

1. C.F.D. Control Reduced susceptibility of Staphylococcus aureus to vancomycin-Japan, 1996 Morb Mortal Wkly Rep 46 1997 624 626
2. R. Nichols Optimal treatment of complicated skin and skin structure infections J Antimicrob Chemother 44 Suppl. A 1999 19 23
3. K. McClean, G. Sheehan, and G. Harding Intra-abdominal infections: a review Clin Infect Dis 9 1994 100 106
4. R. Nichols Preventing surgical site infections: a surgeon's perspective Emerg Infect Dis 7 2001 220 224
5. E. Smyth, and A. Emmerson Surgical site infection surveillance J Hosp Infect 45 2000 173 184
6. D. Diekema, M. Pfaller, F. Schmitz, J. Smayevsky, J. Bell, and R.N. Jones Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region of the SENTRY antimicrobial surveillance program, 1997-1999 Clin Infect Dis 32 Suppl. 2 2001 S114 S132
7. D. Diemema, M. Pfaller, and R. Jones Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America: SENTRY Antimicrobial Surveillance Program, 1997-2000 Int J Antimicrob Agents 20 6 2002 412 418
8. R. Lewis Soft tissue infections World J Surg 22 1998 146 151
9. T. File Overview of resistance in the 1990s Chest 115 Suppl. 3 1999 3S 8S
10. A. Gales, R. Jones, and M. Pfaller Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: results from the SENTRY antimicrobial surveillance program, 1997-98. SENTRY Study Group Int J Infect Dis 4 2000 75 84
11. A. Karchmer Staphylococcus aureus and vancomycin: the sequel Ann Intern Med 115 1991 739 741
12. R. Jones Resistance patterns among nosocomial pathogens: trends over the past few years Chest 119 Suppl. 2 2001 397S 404S
13. G.J. Moran, R.N. Amii, F.M. Abrahamian, and D.A. Talan Methicillin-resistant Staphylococcus aureus in community-acquired skin infections Emerg Infect Dis 11 6 2005 928 930
14. M. Falagas, L. Barefoot, and J. Griffith Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections Eur J Clin Microbiol Infect Dis 15 1996 913 921
15. E. Ibrahim, G. Sherman, and S. Ward The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting Chest 118 2000 146 155
16. M. Abramson, and D. Sexton Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol 20 1999 408 411
17. T. Lodise, P. McKinnon, and L. Swiderski Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia Clin Infect Dis 36 2003 1418 1423
18. R. Rubin, C. Harrington, and A. Poon The economic impact of Staphylococcus aureus infection in New York City hospitals Emerg Infect Dis 5 1999 9 17
19. H. Chambers, R. Miller, and M. Newman Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy Ann Intern Med 109 1988 619 624
20. J. Fortun, E. Navas, and J. Martinez-Beltran Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: Cloxacillin versus glycopeptides in combination with gentamicin Clin Infect Dis 33 2001 120 125
21. A. Hartstein, M. Mulligan, and V. Morthland Recurrent Staphylococcus aureus bacteremia J Clin Microbiol 30 1992 670 674
22. P. Small, and H. Chambers Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users Antimicrob Agents Chemother 34 1990 1227 1231
23. Synercid [Package insert] 2003 Monarch Pharmaceuticals, Inc Bristol, Tenn
24. Zyvox [package insert] 2003 Pharmacia & Upjohn Company Kalamazoo, Mich
25. J. Weigelt, H.M. Kaafarani, K.M. Itani, and R.N. Swanson Linezolid eradicates MRSA better than vancomycin from surgical-site infections Am J Surg 188 6 2004 760 766
26. Cubicin [package insert] 2003 Cubist Pharmaceuticals Lexington, Mass
27. I. Chopra Glycylcyclines: third-generation tetracycline antibiotics Curr Opin Pharmacol 1 5 2001 464 469
28. T.R. Fritsche, P.A. Strabala, H.S. Sader, M.J. Dowzicky, and R.N. Jones Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates Diagn Microbiol Infect Dis 52 3 2005 209 213
29. M.L. van Ogtrop, D. Andes, T.J. Stamstad, B. Conklin, W.J. Weiss, and W.A. Craig In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY152,288) against various gram-positive and gram-negative bacteria Antimicrob Agents Chemother 44 4 2000 943 949
30. D.J. Biedenbach, M.L. Beach, and R.N. Jones In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases Diagn Microbiol Infect Dis 40 4 2001 173 177
31. J. Solomkin, D. Hemsell, and R. Sweet Evaluation of new anti-infective drugs for the treatment of intra-abdominal infections Clin Infect Dis 15 Suppl. 1 1992 S33 S42
32. C. Nord Incidence and significance intraperitoneal aerobic and anaerobic bacteria Clin Ther 12 Suppl. B 1990 9 20
33. J. Bohnen, J. Solomkin, and E. Dellinger Guidelines for clinical care: anti-infective agents for intra-abdominal infection Arch Surg 127 1992 83 89
34. E. Farthmann, and U. Schoffel Principles and limitations of operative management of intraabdominal infections World J Surg 14 2 1990 210 217
35. N. Shinagawa, A. Nizuno, and K. Mashita Bacteria isolated from intraabdominal infection and their susceptibilities to antimicrobial agents Jpn J Antibiot 47 10 1994 1329 1343
36. K. Aldridge, D. Ashcraft, and K. Cambre Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyomonas, and Peptostrpetococcus species Antimicrob Agents Chemother 45 2001 1238 1243
37. D. Whittmann, M. Schein, and R. Condon Management of secondary peritonitis Ann Surg 224 1 1996 10 18
38. J. Solomkin, J. Mazuski, and E. Baron Guidelines for the selection of anti-infective agent for complicated intra-abdominal infections Clin Infect Dis 37 2003 997 1005
39. J. Mazuski, R. Sawyer, and A. Nathens The surgical infection society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary Surg Infect 3 2002 161 173
40. E. Begg, and M. Barclay Aminoglycosides - 50 years on Br J Clin Pharmacol 39 6 1995 597 603
41. P. Benfield, and P. Chrisp Imipenem/cilistatin: a pharmacoeconomic appraisal of its use in intra-abdominal infections Pharmacoeconomics 1 1992 443 459
42. K. Bush, and M. Macielag New approaches in the treatment of bacterial infections Curr Opin Chem Biol 4 4 2000 433 439
43. N. Woodford Biological counterstrike: antibiotic resistance mechanisms of Gram-positive cocci Clin Microbiol Infect 11 Suppl. 3 2005 2 21
44. A.C. Gales, and R.N. Jones Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates Diagn Microbiol Infect Dis 36 1 2000 19 36
45. C.R. Dean, M.A. Visalli, S.J. Projan, P.E. Sum, and P.A. Bradford Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1 Antimicrob Agents Chemother 47 3 2003 972 978
46. R.G. Postier, S.L. Green, S.R. Klein, E.J. Ellis-Grosse, E. Loh the Tigecycline-200 Study Group A multicenter, randomized, open-label safety and efficacy study of tigecycline dosages for complicated skin and skin structure infections in hospitalized patients Clin Therapeut 26 5 2004 704 714
47. Breedt J, Teras J, Gardovskis J, Maritz FJ, Vaasna T, Ross DP. Safety and efficacy of tigecycline in the treatment of skin and skin structure infections: results of a double-blind phase III comparison study with vancomycin/aztroenam. Antimicrob Agents Chemother 2005; 49: 4658-4666.
48. S. Sacchidanand, R.L. Penn, J. Embil, M.E. Campos, E.J. Ellis-Grosse, and E. Loh Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3 randomised double-blind trial Int J Infect Dis 9 5 2005 251 261
49. M.E. Oliva, A. Rekha, A. Yellin, J. Pasternak, M.E. Campos, and G. Rose A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections BMC Infect Dis 2005 10.1186/1471-2334-5-88
50. P. Fomin, M. Beuran, A. Gradauskas, G. Basauskas, A. Datenko, and N. Dartois Tigecycline is efficacious in the treatment of complicated intra-abdominal infections Int J Surg 3 1 2005 35 47